Home / Publication / Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

論文

Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Author(s): John Gibbs, Sameer Doshi, Mita Kuchimanchi, Anita Grover, Maurice Emery, Michael Dodds, Megan Gibbs, Ransi Somaratne, Scott Wasserman, Dirk Blom

Year: 2016年11月15日

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

ブログ

Powered by Translations.com GlobalLink Web Software

Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Building PK/PD Workflows with Cloud and AI – APAC Webinar

Phoenix Roadshow 2025 – Copenhagen

The Reference-scaled Average Bioequivalence (RSABE) Approach

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

メルマガ登録

クイックアクセス

ソリューション

お問合せ